Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.
about
The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenA potential gender bias in assessing quality of life - a standard gamble experiment among university studentsCost-effectiveness of tenofovir as first-line antiretroviral therapy in India.A Systematic Review of the Economic and Humanistic Burden of Gout.Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System PerspectiveWhich health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trialBaseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trialValidation of two generic patient-reported outcome measures in patients with type 2 diabetesThe Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus.Impact evaluation and association with EuroQol 5D health-related utility values in Ménière's disease.Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD)Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study.Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trialCost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United KingdomHealth utility values associated with diabetic retinopathy.Prevalence and impact of chronic widespread pain in the Bangladeshi and White populations of Tower Hamlets, East London.Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspectiveThe Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes.Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in SpainThe use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus.A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review.IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes.Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
P2860
Q30654773-CF0AAFA7-6FB7-44F8-9964-6E061B0A5702Q33732593-9AF0C821-9C3A-4E69-9AAA-3107E2A498DEQ33742403-9631CD74-B1AD-4FD1-9536-8E9695E2A83BQ34726534-D21D0598-76AF-456A-A438-852766434BDFQ35560401-C030EC24-EB13-4682-BB21-C2277A2F8EC3Q35575721-980DC6BA-625B-4B5E-A084-A40394EECFE7Q35629910-7227A068-E1D5-46D6-98EE-0FE8B9FDDD3CQ35833876-ECA6982C-BBC3-4141-9EF0-5D31D1E061ECQ35945237-BE0F8EE7-410B-400E-B663-793DD4DAFBB2Q36091640-BBBFB1DA-9444-496B-8780-5D7D3F44381BQ36093328-CCE48B56-6741-4D31-AE6B-5EC5A6117316Q36134684-8B6234B4-7561-4D14-9EB4-24F98E8C3581Q36308048-A8BA5F31-DA51-4173-B101-CED95FA86C51Q36334618-26C75E9F-CB5D-439D-914B-B41666EC9DEBQ36489848-DA111D0C-E4B2-4563-BF98-593659D1CACFQ36519203-D59F9A4F-6749-4E65-B87D-578C4A254DBCQ36627942-AC93DEA2-E733-4644-A499-A0DCACD96841Q36807446-AEBA0215-E628-42B6-B285-5A5E84F1561AQ36897192-23F09B41-B008-4C4A-A929-709224883BB9Q37111972-32D4E710-DE88-4209-92F9-1BEAE66620B4Q37115088-D4ED0BDD-37E1-4A95-8FD9-D4BDF0313D3FQ37207605-D14CFD17-91A2-4C19-A0F5-C62AC7E64997Q37303680-1306F3DE-707A-4518-9749-53735D3AE29BQ37639302-4B985BC4-CC38-4BE7-9F12-40FA165E0F36Q37689556-6580A7C6-1091-4146-807E-97159524CB3CQ37737468-6E9E88B5-D905-4540-A6BF-F1F5D55FD397Q37851559-4042C7D6-ECFA-49E8-B452-541F69D1524CQ37862622-6775B121-BAD8-4449-824A-1504BA1A6E71Q38052636-78B0E3EA-5706-4332-8267-A920EA61C2F8Q38306101-08BDA5CC-9F8B-4771-BC20-99A5D48AB0ABQ38738725-291613F3-3F22-43B7-A352-0AA01E020F62Q38765656-CC6AE47E-0AEC-4F3F-8A72-7915D2D4201AQ38775589-BE324AFB-2769-461A-9AFC-CAB6C10C24F5Q38907289-6A340071-C31D-4151-86C5-71B42B113521Q39462093-BBF9918A-3B99-4793-A8A2-E51659A45D79Q39571328-D5ED1A79-2875-4698-B313-7EFAD78D5D01Q39645469-4AFC349E-F161-4EB9-BCF9-2A9700962B31Q39738725-1998906C-2CDC-4E62-B98A-DF0DCE95ED26Q39743309-1663A0A3-D50D-4B03-96CB-E8F286C8DF90Q39791634-69B327ED-1A87-41C6-9993-3380B9ECB8D8
P2860
Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Modelling EuroQol health-relat ...... omplications from CODE-2 data.
@ast
Modelling EuroQol health-relat ...... omplications from CODE-2 data.
@en
type
label
Modelling EuroQol health-relat ...... omplications from CODE-2 data.
@ast
Modelling EuroQol health-relat ...... omplications from CODE-2 data.
@en
prefLabel
Modelling EuroQol health-relat ...... omplications from CODE-2 data.
@ast
Modelling EuroQol health-relat ...... omplications from CODE-2 data.
@en
P356
P1433
P1476
Modelling EuroQol health-relat ...... omplications from CODE-2 data.
@en
P2093
Adrian Bagust
Sophie Beale
P304
P356
10.1002/HEC.910
P407
P577
2005-03-01T00:00:00Z